The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, D. Western Therapeutics Institute's share price is 円81.00.
D. Western Therapeutics Institute's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was 円1.99. Hence, D. Western Therapeutics Institute's PS Ratio for today is 40.76.
Good Sign:
D. Western Therapeutics Institute Inc stock PS Ratio (=10.01) is close to 1-year low of 10.01.
During the past 13 years, D. Western Therapeutics Institute's highest 3-Year average Revenue per Share Growth Rate was 60.30% per year. The lowest was -24.80% per year. And the median was 9.30% per year.
Back to Basics: PS Ratio
D. Western Therapeutics Institute (TSE:4576) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
D. Western Therapeutics Institute PS Ratio Related Terms
D. Western Therapeutics Institute PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, D. Western Therapeutics Institute's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
D. Western Therapeutics Institute PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's PS Ratio distribution charts can be found below:
* The bar in red indicates where D. Western Therapeutics Institute's PS Ratio falls into.
D. Western Therapeutics Institute PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
D. Western Therapeutics Institute's Share Price of today is 円81.00. D. Western Therapeutics Institute's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1.99.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
D. Western Therapeutics Institute (TSE:4576) has a PS Ratio of 40.76 as of Jul. 13, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on D. Western Therapeutics Institute and its competitors. This is 80% above median its historical median of 22.69. Over the past decade, D. Western Therapeutics Institute's PS Ratio has ranged from 4.61 to 115.35. According to the industry distribution chart, D. Western Therapeutics Institute ranks #708 out of 930 companies in the Biotechnology industry, placing it in the top 76.1%.
Is D. Western Therapeutics Institute's PS Ratio too high?
D. Western Therapeutics Institute's current PS Ratio of 40.76 is 80% above median its 10-year median of 22.69. Over the past 10 years, this metric has ranged from a low of 4.61 to a high of 115.35. The Biotechnology industry median PS Ratio is 9.49. D. Western Therapeutics Institute's value of 40.76 is 329.5% above this industry median. Based on the distribution chart, D. Western Therapeutics Institute ranks #708 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, D. Western Therapeutics Institute has a GF Score™ of 45/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, D. Western Therapeutics Institute ranks #708 out of 930 companies for PS Ratio. This places D. Western Therapeutics Institute in the lower half of its industry. The industry median PS Ratio is 9.49. D. Western Therapeutics Institute's value of 40.76 is 329.5% above this benchmark. Historically, D. Western Therapeutics Institute's own PS Ratio has ranged from 4.61 to 115.35 over the past decade. While the company's 10-year median is 22.69 vs. the industry median of 9.49, D. Western Therapeutics Institute has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.49, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. D. Western Therapeutics Institute's current PS Ratio of 40.76 is 329.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on D. Western Therapeutics Institute and its competitors. For the Biotechnology industry, the median PS Ratio is 9.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. D. Western Therapeutics Institute's current PS Ratio is 40.76, which is 80% above median its own 10-year median of 22.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
Based on GuruFocus' analysis, D. Western Therapeutics Institute (TSE:4576) is currently considered Modestly Overvalued. The stock's GF Value™ is 円68.85, compared to a current price of 円81.00 — trading 17.6% above its estimated fair value. The current PS Ratio is 40.76, which is 80% above median its 10-year median of 22.69 and 329.5% above the Biotechnology industry median of 9.49. D. Western Therapeutics Institute's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For D. Western Therapeutics Institute (TSE:4576), the current PS Ratio is 40.76 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is D. Western Therapeutics Institute (TSE:4576) Overvalued in 2026?
Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued.
The current stock price of 円81.00 is trading 17.6% above its estimated GF Value™ of 円68.85.
GuruFocus considers D. Western Therapeutics Institute to be Modestly Overvalued.
Key valuation signals for TSE:4576:
PS Ratio: 40.76 (80% above median its 10-year median of 22.69)
GF Value™: 円68.85 vs. price of 円81.00 (17.6% above fair value)
Industry Position: 329.5% above the Biotechnology median (#708 of 930)
No single metric tells the full story. See the TSE:4576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
D. Western Therapeutics Institute Business Description
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
45GF Score
Get the complete analysis for TSE:4576
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4576 has been successfully added to your 
